LT3251675T - Šlapimo rūgšties (kaupimosi) arba podagros ligos prevencija arba gydymas - Google Patents

Šlapimo rūgšties (kaupimosi) arba podagros ligos prevencija arba gydymas

Info

Publication number
LT3251675T
LT3251675T LTEP16742632.9T LT16742632T LT3251675T LT 3251675 T LT3251675 T LT 3251675T LT 16742632 T LT16742632 T LT 16742632T LT 3251675 T LT3251675 T LT 3251675T
Authority
LT
Lithuania
Prior art keywords
accumulation
prevention
treatment
uric acid
gout disease
Prior art date
Application number
LTEP16742632.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Qian Zhang
Zhenhua Huang
Jinrong Liu
Shuangshuang CHI
Original Assignee
Shanton Pharma Pte. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanton Pharma Pte. Ltd. filed Critical Shanton Pharma Pte. Ltd.
Publication of LT3251675T publication Critical patent/LT3251675T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP16742632.9T 2015-01-30 2016-01-28 Šlapimo rūgšties (kaupimosi) arba podagros ligos prevencija arba gydymas LT3251675T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510048096 2015-01-30
CN201510080714 2015-02-13
CN201510079809 2015-02-13
CN201510216089 2015-04-30
PCT/CN2016/000061 WO2016119570A1 (zh) 2015-01-30 2016-01-28 尿酸性或痛风性疾病的预防或治疗

Publications (1)

Publication Number Publication Date
LT3251675T true LT3251675T (lt) 2021-07-12

Family

ID=56542370

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16742632.9T LT3251675T (lt) 2015-01-30 2016-01-28 Šlapimo rūgšties (kaupimosi) arba podagros ligos prevencija arba gydymas

Country Status (26)

Country Link
US (1) US10322132B2 (cg-RX-API-DMAC10.html)
EP (1) EP3251675B1 (cg-RX-API-DMAC10.html)
JP (1) JP6678685B2 (cg-RX-API-DMAC10.html)
KR (1) KR102128810B1 (cg-RX-API-DMAC10.html)
CN (1) CN107206002B (cg-RX-API-DMAC10.html)
AU (1) AU2016212625B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017016065A2 (cg-RX-API-DMAC10.html)
CA (1) CA2973746C (cg-RX-API-DMAC10.html)
CY (1) CY1124383T1 (cg-RX-API-DMAC10.html)
DK (1) DK3251675T3 (cg-RX-API-DMAC10.html)
EA (1) EA034139B1 (cg-RX-API-DMAC10.html)
ES (1) ES2881872T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20211007T1 (cg-RX-API-DMAC10.html)
HU (1) HUE054741T2 (cg-RX-API-DMAC10.html)
IL (1) IL253726B2 (cg-RX-API-DMAC10.html)
LT (1) LT3251675T (cg-RX-API-DMAC10.html)
MA (1) MA41431B1 (cg-RX-API-DMAC10.html)
MX (1) MX380301B (cg-RX-API-DMAC10.html)
PL (1) PL3251675T3 (cg-RX-API-DMAC10.html)
PT (1) PT3251675T (cg-RX-API-DMAC10.html)
SG (2) SG11201705889VA (cg-RX-API-DMAC10.html)
SI (1) SI3251675T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100359T1 (cg-RX-API-DMAC10.html)
TW (1) TWI680761B (cg-RX-API-DMAC10.html)
WO (1) WO2016119570A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201704600B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12566174B2 (en) 2017-05-11 2026-03-03 The Research Foundation For The State University Of New York Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid
AU2024229006A1 (en) 2023-02-27 2025-09-18 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor
CN116650490B (zh) * 2023-06-07 2025-05-20 中国人民解放军海军军医大学 化合物mt-1207在降低尿酸方面的应用
EP4497439A1 (en) * 2023-07-28 2025-01-29 Universitat de les Illes Balears Compounds for the treatment or prevention of gout
TWI902254B (zh) * 2024-05-16 2025-10-21 新加坡商珊頓醫藥科技新加坡公司 化合物8-氯-3-戊基-3,7-二氫-1h-嘌呤-2,6-二酮的晶型及其製備方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
CA2556073C (en) 2004-02-14 2012-01-10 Smithkline Beecham Corporation 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
AR061626A1 (es) * 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
CN101479273B (zh) 2006-06-23 2011-11-30 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
WO2010071865A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20110136835A1 (en) * 2009-09-14 2011-06-09 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia

Also Published As

Publication number Publication date
US10322132B2 (en) 2019-06-18
KR102128810B1 (ko) 2020-07-02
PT3251675T (pt) 2021-05-25
TWI680761B (zh) 2020-01-01
EP3251675B1 (en) 2021-04-21
WO2016119570A1 (zh) 2016-08-04
HK1244434A1 (zh) 2018-08-10
EA034139B1 (ru) 2020-01-09
CA2973746A1 (en) 2016-08-04
SMT202100359T1 (it) 2021-07-12
AU2016212625B2 (en) 2020-03-26
EP3251675A4 (en) 2018-06-20
HRP20211007T1 (hr) 2021-09-17
IL253726B2 (en) 2023-07-01
CN107206002A (zh) 2017-09-26
JP6678685B2 (ja) 2020-04-08
MA41431B1 (fr) 2021-05-31
IL253726A0 (en) 2017-09-28
MX2017009853A (es) 2017-11-01
KR20170106485A (ko) 2017-09-20
TW201628623A (zh) 2016-08-16
SI3251675T1 (sl) 2021-08-31
JP2018503691A (ja) 2018-02-08
EA201791714A1 (ru) 2017-11-30
DK3251675T3 (da) 2021-06-28
MA41431A (fr) 2017-12-06
SG10201907026RA (en) 2019-09-27
ES2881872T3 (es) 2021-11-30
BR112017016065A2 (pt) 2018-04-03
US20170326148A1 (en) 2017-11-16
MX380301B (es) 2025-03-12
ZA201704600B (en) 2020-07-29
HUE054741T2 (hu) 2021-09-28
CA2973746C (en) 2020-03-24
SG11201705889VA (en) 2017-08-30
IL253726B1 (en) 2023-03-01
AU2016212625A1 (en) 2017-07-27
EP3251675A1 (en) 2017-12-06
CY1124383T1 (el) 2022-07-22
CN107206002B (zh) 2019-07-16
PL3251675T3 (pl) 2021-11-02
HK1245146A1 (en) 2018-08-24

Similar Documents

Publication Publication Date Title
IL283837A (en) Augmented acid alpha-glucosidase for the treatment of pompe disease
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
IL253945A0 (en) kdm1a inhibitors to treat the disease
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
EP3313325A4 (en) IMPLANTABLE EQUIPMENT FOR THE TREATMENT OF SINUSITIS
HUE058737T2 (hu) Eljárások arenaviridae vírusok okozta fertõzések kezelésére
EP3261641A4 (en) PANKREATITISBEHANDLUNG
HRP20181130T1 (hr) Postupci za liječenje infekcija virusom filoviridae
IL257960A (en) A group of substances used to treat or prevent hyperuricemia or gout
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
IL253726B1 (en) Preparations for the treatment of inflammatory diseases related to uric acid
EP3612133A4 (en) Implantable scaffolds for treatment of sinusitis
DK3406258T3 (da) Medikament til anvendelse til behandling af urinsyregigt
LT3322438T (lt) Il-8 inhibitoriai, skirti naudoti tam tikrų urologinių susirgimų gydymui
GB201515244D0 (en) Treatment of inflammatory disease or condition
KR101583452B9 (ko) 위장질환 치료용 의약 조성물
DK2975004T3 (da) Syrespildevandsbehandling
DK3206694T3 (da) Anvendelse af neridronsyre eller dens salt til behandling af osteoarthrose
EP3313519A4 (en) TREATMENT OF MYOPATHY
LT3397273T (lt) Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui
IS050130A (is) Ferli við meðhöndlun fastra efna úr söltu skólpi
GB201504413D0 (en) Treatment of disease